The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
PADCEV (Astellas Pharma Australia Pty Ltd)
Product name
PADCEV
Date registered
Evaluation commenced
Decision date
Approval time
240 (255 working days)
Active ingredients
enfortumab vedotin
Registration type
NCE/NBE
Indication
PADCEV as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor-1 or programmed death-ligand-1 inhibitor.